Tesamorelin Approved for Lipodystrophy

By Liz Highleyman
From San Francisco AIDS Foundation

Summer/Fall 2010

In November, the FDA approved tesamorelin (Egrifta; formerly known as TH9507) for treatment of a type of lipodystrophy in HIV positive people taking antiretroviral therapy. Tesamorelin is a synthetic growth hormone-releasing factor that stimulates the pituitary gland to secrete more human growth hormone.

Approval was based on clinical trials showing that daily tesamorelin injections significantly decreased visceral abdominal fat and lowered total cholesterol levels. The drug was generally well-tolerated and caused fewer side effects than growth hormone itself. For more information, see "Drug Watch: Tesamorelin Update," in this issue.

Liz Highleyman (liz@black-rose.com) is a freelance medical writer based in San Francisco.

Theratechnologies Withdraw EU Application for Tesamorelin (Egrifta)

Drug Watch: Tesamorelin Update

This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.

An HIVer's Guide to Metabolic Complications

More on Egrifta (Tesamorelin)

"You don't have to fight this fight by yourself." Watch Susan's Story >

Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade

HIV Undetectable = Untransmittable (U=U) Fact Sheet

Who Tends to Gain Weight With HIV Treatment?

HIV/AIDS Cure: The Basics

Drug Pricing Program That Supports AIDS Service Organizations Is Under Attack

More >>

TheBody.com App

Get Our Newsletters

My Health Tracker

Medication and Health Reminders

Assess Your Risk for HIV

The Body is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.